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1. Introduction {#ags312009-sec-0001}
===============

In the early 1990s, laparoscopic surgery for early‐stage cancer was considered feasible in Japan, but it was not known whether an adequate extent of lymph node dissection for more advanced cases could be achieved by laparoscopic procedures.[1](#ags312009-bib-0001){ref-type="ref"} In the Japanese Society for Cancer of the Colon and Rectum Guidelines 2010,[2](#ags312009-bib-0002){ref-type="ref"} laparoscopic surgery is suitable for D2, D1 or D0 resection of colon and RS cancer and is strongly indicated for the treatment of cStage 0 to cStage I disease. However, according to the national survey conducted by the Japanese Society of Endoscopic Surgery (JSES),[3](#ags312009-bib-0003){ref-type="ref"} the percentage of more advanced cancers (T2 or higher) accounting for the procedure has increased to over 50% of the total cases. Although many patients with T4 colon cancer are included in those cases, the risk of peritoneal dissemination after surgery remains unclear. The aim of this retrospective study was to evaluate the validity of laparoscopic surgery for patients with T4a colon cancer.

2. Methods {#ags312009-sec-0002}
==========

Seven hundred and eleven patients with T3 or T4a colon cancer, aged 80 years or younger, underwent curative resection (open surgery in 512 and laparoscopic surgery in 199) at the four Jikei University hospitals between 2006 and 2012, and their risk factors for peritoneal dissemination after surgery were evaluated retrospectively. The medical records of all patients were reviewed and classified according to the *Japanese Classification of Colorectal Carcinoma*.[4](#ags312009-bib-0004){ref-type="ref"} According to this classification, T3 corresponds to invasion of the subserosa and T4a to serosal invasion, excluding direct extension into adjacent structures or organs, which is classified as T4b.

No special procedure to cover serosal invasion to prevent detachment of cancer cells to the peritoneal cavity was added during surgery in patients with T4a colon cancer. Choice of surgical procedure, laparoscopic surgery or open surgery, was based on the preference of the operators. However, laparoscopic surgery was aggressively chosen in cases in which expert laparoscopic surgeons authorized by JSES were operators or assistants.

2.1. Follow up after surgery and postoperative adjuvant chemotherapy {#ags312009-sec-0003}
--------------------------------------------------------------------

All patients were followed for 5 years with measurement of serum carcinoembryonic antigen every 3 months, computed tomography (CT) every 6 months and colonoscopy every 12 months. When we suspected any recurrence, CT and positron emission tomography were carried out at that time.

For 6 months after surgery, patients with stage III disease received oral S‐1 (Taiho Pharmaceuticals Co. Ltd, Tokyo, Japan) or capecitabine (Xeloda; Hoffmann‐La Roche, Basel, Switzerland), whereas patients with stage II disease received no adjuvant chemotherapy.

2.2. Statistical analysis {#ags312009-sec-0004}
-------------------------

Continuous variables were expressed as mean and range. Wilcoxon rank‐sum test was used for comparison of continuous variables and the chi‐squared test was used for comparison of categorical data. Postoperative relapse‐free survival rates were examined by the Kaplan--Meier method and log--rank analysis. Variables affecting peritoneal dissemination after surgery were analyzed using the Cox proportional hazards regression. A *P*‐value of less than.05 was considered to indicate significance. All data were analyzed with the computer program IBM SPSS Statistics, version 22.0 (IBM Japan, Ltd, Tokyo, Japan).

3. Results {#ags312009-sec-0005}
==========

3.1. Comparison of patient characteristics between T3 and T4a {#ags312009-sec-0006}
-------------------------------------------------------------

Between patients with T4a disease and patients with T3 disease, no significant difference was identified in age, gender, tumor location, macroscopic type of tumor, tumor diameter, and pathological type (Table [1](#ags312009-tbl-0001){ref-type="table-wrap"}). The groups of patients did differ significantly in surgical approach, operation time, intraoperative bleeding, lymph node metastasis, and postoperative recurrence rates of peritoneal dissemination and liver metastasis (Table [1](#ags312009-tbl-0001){ref-type="table-wrap"}). Median follow‐up period was 78 months (range 36--130 months). Frequency of peritoneal dissemination after surgery was less than one percent for patients with T3 and five percent for those with T4a (Table [1](#ags312009-tbl-0001){ref-type="table-wrap"}).

###### 

Clinicopathological characteristics of patients with T3 and T4a colon cancer

  Variable                                   T3 (*n* = 589)    T4a (*n* = 122)   *P*‐value
  ------------------------------------------ ----------------- ----------------- -----------
  Age (years)                                66.0 (25--80)     66.3 (32--80)     0.565
  Gender                                                                         
  Male                                       334 (57)          77 (63)           0.192
  Female                                     255 (43)          45 (37)           
  Tumor location                                                                 
  Cecum                                      65 (11)           16 (13)           0.116
  Ascending colon                            170 (29)          30 (25)           
  Transverse colon                           88 (15)           29 (24)           
  Descending colon                           59 (10)           8 (6)             
  Sigmoid colon                              207 (35)          39 (32)           
  Surgical approach                                                              
  Open surgery                               412 (70)          100 (82)          0.007
  Laparoscopic surgery                       177 (30)          22 (18)           
  Operation time (min)                       185.0 (45--595)   170.5 (65--487)   0.036
  Intraoperative blood loss (mL)             167.2 (0--3210)   248.6 (0--3348)   0.011
  Macroscopic type                                                               
  I                                          25 (4)            2 (2)             0.246
  II                                         542 (92)          113 (93)          
  III                                        22 (4)            7 (5)             
  Tumor diameter (mm)                        47.7 (13--210)    51.3 (20--170)    0.112
  Pathological type                                                              
  Well‐differentiated adenocarcinoma         173 (29)          41 (33)           0.100
  Moderately differentiated adenocarcinoma   383 (65)          73 (60)           
  Poorly differentiated adenocarcinoma       15 (3)            7 (6)             
  Others                                     18 (3)            1 (1)             
  Stage                                                                          
  II                                         337 (57)          43 (35)           0.001\>
  III                                        252 (43)          79 (65)           
  Recurrence after surgery                   55 (9)            34 (28)           0.001\>
  Recurrent site                                                                 
  Peritoneum                                 4 (1\>)           6 (5)             0.001\>
  Liver                                      30 (5)            20 (16)           0.001\>
  Lung                                       14 (2)            6 (5)             0.122
  Others                                     7 (1)             2 (2)             0.685

Data are presented as mean (range) or as *n* (%).
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3.2. Comparison of patient postoperative relapse‐free survival rate between T3 and T4a {#ags312009-sec-0007}
--------------------------------------------------------------------------------------

The 5‐year relapse‐free survival rates were 90.5% for patients with T3 and 72.6% for patients with T4a (Fig. [1](#ags312009-fig-0001){ref-type="fig"}). There was a significant difference in postoperative relapse‐free survival rates between T3 and T4a according to log--rank analysis (*P* \< 0.001).

![Kaplan--Meier relapse‐free survival curves for patients with T4a and T3 colon cancer](AGS3-1-69-g001){#ags312009-fig-0001}

3.3. Comparison between open and laparoscopic surgery in patients with T3 {#ags312009-sec-0008}
-------------------------------------------------------------------------

Between patients with T3 who received open surgery and laparoscopic surgery, no significant differences were identified in age, gender, macroscopic type of tumor, pathological type, lymph node metastasis and postoperative recurrence rates or sites, whereas significant differences were achieved in tumor location, operation time, intraoperative bleeding, tumor diameter, and pathological type (Table [2](#ags312009-tbl-0002){ref-type="table-wrap"}). Tumor diameters in the open surgery group were significantly larger than in the laparoscopic surgery group.

###### 

Comparison between open and laparoscopic surgery in patients with T3 colon cancer

  Variable                                   Open surgery (*n* = 412)   Laparoscopic surgery (*n* = 177)   *P*‐value
  ------------------------------------------ -------------------------- ---------------------------------- -----------
  Age (years)                                67.9 (32--80)              64.9 (25--80)                      0.001
  Gender                                                                                                   
  Male                                       235 (57)                   99 (56)                            0.804
  Female                                     177 (43)                   78 (44)                            
  Tumor location                                                                                           
  Cecum                                      37 (9)                     28 (16)                            0.001\>
  Ascending colon                            132 (32)                   40 (23)                            
  Transverse colon                           70 (17)                    16 (9)                             
  Descending colon                           41 (10)                    16 (9)                             
  Sigmoid colon                              132 (32)                   77 (43)                            
  Operation time (min)                       173.1 (45--415)            212.8 (85--595)                    0.001\>
  Intraoperative blood loss (mL)             214.2 (0--1950)            58.2 (0--3210)                     0.001\>
  Macroscopic type                                                                                         
  I                                          15 (4)                     10 (6)                             0.525
  II                                         381 (92)                   161 (91)                           
  III                                        16 (4)                     6 (3)                              
  Tumor diameter (mm)                        51.9 (13--210)             37.4 (10--120)                     0.001\>
  Pathological type                                                                                        
  Well‐differentiated adenocarcinoma         128 (31)                   45 (25)                            0.031
  Moderately differentiated adenocarcinoma   255 (62)                   128 (72)                           
  Poorly differentiated adenocarcinoma       14 (3)                     1 (1)                              
  Others                                     15 (4)                     3 (2)                              
  Stage                                                                                                    
  II                                         227 (55)                   110 (62)                           0.113
  III                                        185 (45)                   67 (38)                            
  Recurrence after surgery                   42 (10)                    13 (7)                             0.276
  Recurrent site                                                                                           
  Peritoneum                                 2 (1\>)                    2 (1\>)                            0.744
  Liver                                      23 (6)                     7 (4)                              0.410
  Lung                                       13 (3)                     1 (1\>)                            0.068
  Others                                     4 (1)                      3 (2)                              0.742

Data are presented as mean (range) or as *n* (%).
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3.4. Comparison of patient postoperative relapse‐free survival rate in T3 between open and laparoscopic surgery {#ags312009-sec-0009}
---------------------------------------------------------------------------------------------------------------

The 5‐year relapse‐free survival rates of patients with T3 were 92.5% for patients after laparoscopic surgery and 90.1% for patients after open surgery (Fig. [2](#ags312009-fig-0002){ref-type="fig"}). There was no significant difference in postoperative relapse‐free survival rate between the two groups by log--rank analysis (*P *= 0.338).

![Kaplan--Meier relapse‐free survival curves for patients with T3 colon cancer who received laparoscopic surgery or open surgery](AGS3-1-69-g002){#ags312009-fig-0002}

3.5. Comparison between open and laparoscopic surgery in patients with T4a {#ags312009-sec-0010}
--------------------------------------------------------------------------

Between patients with T4 who received open surgery and patients who received laparoscopic surgery, no significant differences were found in age, tumor location, operation time, macroscopic type of tumor, tumor diameter, pathological type, lymph node metastasis and postoperative recurrence rate or site (Table [3](#ags312009-tbl-0003){ref-type="table-wrap"}), whereas significant differences were identified in gender and intraoperative bleeding (Table [3](#ags312009-tbl-0003){ref-type="table-wrap"}). Intraoperative blood loss in the open surgery group was significantly greater than in the laparoscopic surgery group.

###### 

Comparison between open and laparoscopic surgery in patients with T4a colon cancer

  Variable                                   Open surgery (*n* = 100)   Laparoscopic surgery (*n* = 22)   *P*‐value
  ------------------------------------------ -------------------------- --------------------------------- -----------
  Age (years)                                67.2 (32--80)              62.5 (40--77)                     0.062
  Gender                                                                                                  
  Male                                       68 (68)                    9 (41)                            0.017
  Female                                     32 (32)                    13 (59)                           
  Tumor location                                                                                          
  Cecum                                      12 (12)                    4 (18)                            0.426
  Ascending colon                            23 (23)                    7 (32)                            
  Transverse colon                           27 (27)                    2 (9)                             
  Descending colon                           7 (7)                      1 (5)                             
  Sigmoid colon                              31 (31)                    8 (36)                            
  Operation time (min)                       166.8 (65--487)            187.6 (110--280)                  0.112
  Intraoperative blood loss (mL)             298.0 (0--3348)            24.6 (0--240)                     0.013
  Macroscopic type                                                                                        
  I                                          2 (2)                      0 (0)                             0.343
  II                                         91 (91)                    22 (100)                          
  III                                        7 (7)                      0 (0)                             
  Tumor diameter (mm)                        52.3 (20--187)             46.6 (21--125)                    0.410
  Pathological type                                                                                       
  Well‐differentiated adenocarcinoma         31 (31)                    10 (45)                           0.391
  Moderately differentiated adenocarcinoma   61 (61)                    12 (55)                           
  Poorly differentiated adenocarcinoma       7 (7)                      0 (0)                             
  Others                                     1 (1)                      0 (0)                             
  Stage                                                                                                   
  II                                         36 (36)                    7 (32)                            0.710
  III                                        64 (64)                    15 (68)                           
  Recurrence after surgery                   30 (30)                    4 (18)                            0.392
  Recurrent site                                                                                          
  Peritoneum                                 6 (6)                      0 (0)                             0.526
  Liver                                      16 (16)                    4 (18)                            1.000
  Lung                                       6 (6)                      0 (0)                             0.526
  Others                                     2 (2)                      0 (0)                             1.000

Data are presented as mean (range) or as *n* (%).
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3.6. Comparison of postoperative relapse‐free survival rate of patients with T4a between open and laparoscopic surgery {#ags312009-sec-0011}
----------------------------------------------------------------------------------------------------------------------

The 5‐year relapse‐free survival rate of patients with T4a was 81.8% for patients who underwent laparoscopic surgery and 71.5% for patients who underwent open surgery (Fig. [3](#ags312009-fig-0003){ref-type="fig"}), showing no significant difference by log--rank analysis (*P *= 0.389).

![Kaplan--Meier relapse‐free survival curves for patients with T4a colon cancer who received laparoscopic surgery or open surgery](AGS3-1-69-g003){#ags312009-fig-0003}

3.7. Cox proportional hazards regression for peritoneal dissemination after surgery {#ags312009-sec-0012}
-----------------------------------------------------------------------------------

To determine the variables affecting peritoneal dissemination after surgery, 11 variables (age, gender, tumor location, operative time, intraoperative blood loss, macroscopic type, tumor diameter, pathological type, serosal invasion, number of lymph node metastases, and surgical approach) were analyzed using the Cox proportional hazards regression, because the stage identifies depth of tumor and number of lymph node metastases. Only three factors, macroscopic type (*P *= 0.016), serosal invasion (*P *= 0.017) and number of lymph node metastases (*P *= 0.009), were independent contributing factors to peritoneal dissemination after surgery (Table [4](#ags312009-tbl-0004){ref-type="table-wrap"}).

###### 

Multivariate analyses using Cox proportional hazards regression model for peritoneal dissemination after surgery

  Variable                                        Hazard ratio (95% confidence interval)   *P*‐value
  ----------------------------------------------- ---------------------------------------- -----------
  Age (years)                                                                              
  ≦70                                             2.399 (0.584--9.865)                     0.225
  \>70                                            1                                        
  Gender                                                                                   
  Male                                            1.085 (0.279--4.209)                     0.906
  Female                                          1                                        
  Tumor location                                                                           
  Left colon                                      0.999 (0.479--2086)                      0.999
  Right colon                                     1                                        
  Operation time (min)                                                                     
  ≦180                                            0.726 (0.163--3.231)                     0.674
  \>180                                           1                                        
  Intraoperative blood loss (mL)                                                           
  ≦300                                            1.188 (0.264--5.346)                     0.822
  \>300                                           1                                        
  Macroscopic type                                                                         
  Others                                          7.359 (1.454--37.248)                    0.016
  Type II                                         1                                        
  Tumor diameter (mm)                                                                      
  ≦50                                             0.953 (0.253--3.586)                     0.943
  \>50                                            1                                        
  Pathological type                                                                        
  Well‐ and moderately differentiated carcinoma   0.744 (0.251--2.206)                     0.593
  Others                                          1                                        
  Serosal invasion                                                                         
  Positive                                        5.174 (1.347--19.871)                    0.017
  Negative                                        1                                        
  No. lymph node metastases                                                                
  ≦4                                              7.399 (1.646--33.269)                    0.009
  \>4                                             1                                        
  Surgical approach                                                                        
  Laparoscopic surgery                            1.515 (0.265--8.649)                     0.640
  Open surgery                                    1                                        
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4. Discussion {#ags312009-sec-0013}
=============

Although liver metastasis is the most frequent recurrence pattern after surgery in patients with colon cancer, peritoneal dissemination accounted for 16% of all patients with recurrence, for which serosal invasion may correlate with peritoneal dissemination.[5](#ags312009-bib-0005){ref-type="ref"} The recent frequency of peritoneal dissemination in T4 colon cancer after surgery is unknown.[6](#ags312009-bib-0006){ref-type="ref"} Nishikawa *et al*.[7](#ags312009-bib-0007){ref-type="ref"} reported that 14% of 151 patients with T4 colorectal cancer had positive cytology detected by peritoneal lavage cytology during surgery, and 64.5% of patients with T3 or T4 colorectal cancer with positive peritoneal lavage cytology developed peritoneal dissemination. However, patients with positive cytology who did not develop peritoneal dissemination during the operation could achieve long‐term survival.

In our study, peritoneal dissemination after surgery developed in six patients with T4a (5%), which was very low compared to the previous reports evaluated more than 10 years ago.[5](#ags312009-bib-0005){ref-type="ref"}, [7](#ags312009-bib-0007){ref-type="ref"} Cox proportional hazards regression analysis demonstrated serosal invasion and number of lymph node metastases to be the independent contributing factors for peritoneal dissemination after surgery, whereas the surgical approach failed to demonstrate a significant difference in the postoperative relapse‐free survival rate in the T4a group. Whether we chose laparoscopic or open surgery for the T4a group, the surgical outcome was the same. Therefore, laparoscopic surgery for patients with T4a colon cancer seems justified.

A large number of controlled studies and meta‐analyses have shown that laparoscopic surgery is associated with less pain, early recovery of bowel transit and shorter hospital stay compared to open surgery.[8](#ags312009-bib-0008){ref-type="ref"}, [9](#ags312009-bib-0009){ref-type="ref"}, [10](#ags312009-bib-0010){ref-type="ref"}, [11](#ags312009-bib-0011){ref-type="ref"}, [12](#ags312009-bib-0012){ref-type="ref"} Furthermore, a subset analysis of a randomized trial showed a lower recurrence rate and better survival in patients with stage III colon cancer undergoing laparoscopic surgery compared with open surgery.[13](#ags312009-bib-0013){ref-type="ref"}, [14](#ags312009-bib-0014){ref-type="ref"}, [15](#ags312009-bib-0015){ref-type="ref"}, [16](#ags312009-bib-0016){ref-type="ref"}, [17](#ags312009-bib-0017){ref-type="ref"} In those studies, no additional procedure to cover serosal invasion to prevent the detachment of cancer cells to the peritoneal cavity was used during surgery in either approach.

In conclusion, laparoscopic surgery for patients with T4a colon cancer seems justified because patients with T3 and T4a had comparable postoperative peritoneal dissemination and other recurrences such as liver or lung metastasis.
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